Outcomes with the use of glycoprotein IIb/IIIa inhibitors in non-ST-segment elevation acute coronary syndromes
Center for Outcomes Research; Department of Medicine, Division of Cardiovascular Medicine
Acute Coronary Syndrome; Aged; Cohort Studies; Death, Sudden, Cardiac; Female; Hemorrhage; Hospitalization; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Risk Factors; Stroke; Treatment Outcome
Health Services Research
OBJECTIVE: To compare the characteristics, management, and outcomes of patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS) who would have been eligible for inclusion in clinical trials of glycoprotein (GP) IIb/IIIa inhibitors with those of ineligible patients.
DESIGN: Multinational, prospective, observational study (GRACE, Global Registry of Acute Coronary Events).
SETTING: Patients hospitalised for a suspected acute coronary syndrome and enrolled in GRACE between April 1999 and December 2004.
PATIENTS: 29 039 patients with NSTE ACS.
MAIN OUTCOME MEASURES: Characteristics and outcomes were compared for trial-eligible (75.0%) and trial-ineligible (25.0%) patients.
RESULTS: GP IIb/IIIa inhibitors were administered to 20.0% of eligible and 15.3% of ineligible patients. Compared with eligible patients, ineligible patients who received GP IIb/IIIa inhibitors had significantly higher rates of hospital death (6.8% vs 3.7%) and major bleeding (4.9% vs 2.2%). After adjustment for their higher baseline risk, ineligible patients still experienced higher hospital death rates (adjusted odds ratio (OR) 1.60; 95% confidence interval (CI) 1.01 to 2.39), but not higher bleeding rates, than the eligible group. Use of GP IIb/IIIa inhibitors was associated with a trend towards lower 6-month mortality in eligible (OR 0.86, 95% CI 0.72 to 1.02) and ineligible (OR 0.82, 95% CI 0.65 to 1.05) patients compared with those in whom this therapy was not used.
CONCLUSIONS: GP IIb/IIIa inhibitors were markedly underused in the real-world population, irrespective of whether patients were trial-eligible or not. Despite the higher risk of ineligible patients, the benefits of GP IIb/IIIa inhibitors appear to be no less than in eligible patients.
DOI of Published Version
Heart. 2008 Feb;94(2):159-65. Epub 2007 Jun 17. Link to article on publisher's site
Heart (British Cardiac Society)
Dabbous OH, Anderson FA, Gore JM, Eagle KA, Fox KA, Mehta RH, Goldberg RJ, Agnelli G, Steg PG. (2008). Outcomes with the use of glycoprotein IIb/IIIa inhibitors in non-ST-segment elevation acute coronary syndromes. GRACE Publications. https://doi.org/10.1136/hrt.2006.105783. Retrieved from https://escholarship.umassmed.edu/cor_grace/91